[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 50.16.17.16. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Article
May 12, 1997

History of Fixed-Dose Combination Therapy for Hypertension

Author Affiliations

Winston-Salem, NC

Arch Intern Med. 1997;157(9):1044. doi:10.1001/archinte.1997.00440300166021
Abstract

The excellent historical perspective on fixed-dose combination therapies for hypertension by Epstein and Bakris1 did not include discussion of the earliest combination medications for hypertension. Their article misstated that fixed-dose combinations have always included a diuretic as a component until the release of an angiotensin-converting enzyme inhibitor—calcium antagonist combination this year. A look even further back in history reveals the earlier existence of several nondiuretic combination medications that illustrate the very principles used to justify the resurging interest in combination antihypertensives.

Reserpine and other rauwolfia derivatives were offered in fixed-dose combination with a variety of medications during the 1950s, before diuretics were even approved for the treatment of hypertension. The combination of rauwolfia and veratrum (a parasympathomimetic agent) was marketed as Verapene, a medication that enhances antihypertensive efficacy but avoids side effects by reducing the dose of the component antihypertensives.2 In an era when anxiety and hypertension were

First Page Preview View Large
First page PDF preview
First page PDF preview
×